Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing...
Saved in:
Main Authors: | Prager W, Bee EK, Havermann I, Zschocke I |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/932974b03b53414ebb1a1743670cf9a7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
by: Prager W
Published: (2013) -
Intraoral alveolar submucosal injections of Incobotulinumtoxin A: Relief of therapy-refractory trigeminal neuropathy after tooth extraction
by: Lars Wojtecki, et al.
Published: (2021) -
Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
by: Stengel G, et al.
Published: (2011) -
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
by: Park J, et al.
Published: (2011) -
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
by: Santamato A
Published: (2016)